Exova Group PLC Issue of Equity (9872P)

TIDMEXO

RNS Number : 9872P

Exova Group PLC

24 November 2016

EXOVA GROUP PLC

ISSUE OF EQUITY

Exova Group plc (the "Company") announces that application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 58,824 new ordinary shares of 1 pence each (the "Shares") in the Company for admission on 28 November 2016 to trading on the main market for listed securities of the London Stock Exchange and to listing on the premium listing segment of the Official List maintained by the Financial Conduct Authority. The Shares will rank pari passu with the existing ordinary shares of the Company.

The Shares were issued and allotted on 23 November 2016 to the Exova Group Employee Benefit Trust to satisfy the exercise by Paul Barry, a person discharging managerial responsibilities of the Company ("PDMR"), of his fully-vested award under the Company's Deferred Bonus Plan as set out in the Company's RNS announcement of a dealing by a PDMR dated 24 November 2016.

Following the issue of the Shares, the number of ordinary shares in issue will increase to 250,490,374. For the purposes of the Financial Conduct Authority's Disclosure and Transparency Rules ("DTRs"), the issued ordinary share capital of the Company following this allotment consists of 250,490,374 Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the DTRs.

For and on behalf of Exova Group plc

Date: 24 November 2016

Neil MacLennan

General Counsel & Company Secretary

Telephone: [phone]

About Exova

Exova is one of the world's leading laboratory-based testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK, Exova operates 138 laboratories and offices in 33 countries and employs more than 4,300 people throughout Europe, the Americas, the Middle East, Asia/Asia Pacific and Africa.

Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors ranging from Aerospace to Fire & Building Products; Oil & Gas and Industrials; Infrastructure & Environment; Automotive; and Health Sciences.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEBJBFTMBITBTF

(END) Dow Jones Newswires

November 24, 2016 04:00 ET (09:00 GMT)